If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Biphasic Insulin Aspart 70/30 Helps Poorly Controlled Diabetics Reach Glycaemic Targets: Presented at ADA By Elizabeth Nicholas SAN FRANCISCO -- June 9, 2008 -- More than two-thirds of patients with poorly controlled type 2 diabetes are able to achieve recommended glycaemic levels when they receive biphasic insulin aspart 70/30 in a routine clinical practice setting, researchers said here at the American Diabetes Association (ADA) 68th Scientific Sessions. Joseph Shaban, MD, Windsor Regional Hospital, Windsor, Ontario, described trial results here on June 7 from 17,313 patients who were prescribed premix biphasic insulin aspart by their physician in routine clinical practice as part of the IMPROVE(TM) study. The IMPROVE study is the largest ever global observational study in diabetes. Overall, 27% of participants had not received prior treatment for their diabetes, 67% were on oral antidiabetic drugs alone, and 6% were receiving insulin with or without oral antidiabetic drugs. Some of the insulin regimens included before the study began included basal insulin, bolus insulin, basal/bolus regimen, and human premixed insulin. The mean patient age was 56.1 years, and the mean time of diabetes duration to date was approximately 6 years. Patients across all pretherapy subgroups had an average haemoglobin (Hb) A1C of 9.4%, which was significantly higher than the ADA guideline target of less than 7%. The study found a 2.5% improvement in mean Hb A1C in the total study population at 26 weeks. Patients who had been poorly controlled on prior insulin therapy had larger improvements than patients who were first-time insulin users. Overall, 71% of patients achieved the Hb A1C target of less than or equal to 7%, and 49% reached the Hb A1C goal of less than or equal to 6.5%. The proportion of patients reporting major hypoglycaemic events decreased from 0.7% at baseline to 0.2% after 6 months, which translates into a 71% decrease. No significant weight change was observed. The dose of biphasic insulin aspart 70/30 increased minimally during the trial (0.06 IU/kg) from 0.37 IU/kg at baseline to 0.42 IU/kg at 26 weeks. The investigators used the Diabetes Medication Satisfaction questionnaire (DiabMedSat), to compare quality of life pre- and post-treatment. The questionnaire evaluates relief of burden, relief of symptoms, and effectiveness. In 11,150 patients who completed the questionnaire, the mean patient satisfaction score increased from a baseline score of 57.2 (on a 100-point scale) to 74.5 at 26 weeks. The largest improvement on the DiabMedSat questionnaire was observed in the efficacy domain, while the highest score was observed in the relief of symptoms domain. Greater overall treatment satisfaction will hopefully translate into improved treatment adherence and will encourage diabetes self-management, the investigators concluded. Funding for this study was provided by Novo Nordisk A/S.
Presentation title: NovoMix 30 (BIAsp 30) Improves Glycemic Control in Type 2 Diabetes: Results From the IMPROVE(TM) Study. Abstract 2108]
|
